HER-2 positive

News alerts, weekly reports and conference planners

Entrez ID:

2064

Related biomarkers:

‹

›

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	capecitabine Sensitive: A2 - Guideline NCCN - 1 week (New A2) capecitabine Sensitive : A2 NCCN - 1wk	capecitabine Sensitive: A2 - Guideline NCCN - 1 week capecitabine Sensitive : A2 NCCN - 1 week - (New A2)
HER-2 positive	Cholangiocarcinoma	HER-2 positive	Cholangiocarcinoma	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 1 week (New C3) BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 1wk	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 1 week BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 1 week - (New C3)
HER-2 positive	Esophageal Cancer	HER-2 positive	Esophageal Cancer	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 1 week (New C3) BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 1wk	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 1 week BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 1 week - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	dasatinib + lapatinib Sensitive: D – Preclinical PLoS One - 1 week (New D) dasatinib + lapatinib Sensitive : D PLoS One - 1wk	dasatinib + lapatinib Sensitive: D – Preclinical PLoS One - 1 week dasatinib + lapatinib Sensitive : D PLoS One - 1 week - (New D)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: A1 - Approval Breast - 3 weeks (New C3) ado-trastuzumab emtansine Sensitive : A1 Breast - 3wk	ado-trastuzumab emtansine Sensitive: A1 - Approval Breast - 3 weeks ado-trastuzumab emtansine Sensitive : A1 Breast - 3 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks (New C3) pyrotinib + dalpiciclib Sensitive : C2 ASCO-GI 2023 - 3wk	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 3 weeks pyrotinib + dalpiciclib Sensitive : C2 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 3wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 3wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	olaparib + durvalumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) olaparib + durvalumab Sensitive : C3 ASCO-GI 2023 - 3wk	olaparib + durvalumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks olaparib + durvalumab Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 3wk	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 positive	Salivary Gland Cancer	HER-2 positive	Salivary Gland Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	THP Sensitive: A2 - Guideline THP Sensitive : A2	THP Sensitive: A2 - Guideline THP Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	TCHP Sensitive: A2 - Guideline TCHP Sensitive : A2	TCHP Sensitive: A2 - Guideline TCHP Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + abemaciclib Sensitive: A2 - Guideline trastuzumab + abemaciclib Sensitive : A2	trastuzumab + abemaciclib Sensitive: A2 - Guideline trastuzumab + abemaciclib Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	TCH Sensitive: A2 - Guideline TCH Sensitive : A2	TCH Sensitive: A2 - Guideline TCH Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2
HER-2 positive	Gastroesophageal Cancer	HER-2 positive	Gastroesophageal Cancer	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
HER-2 positive	Esophageal Adenocarcinoma	HER-2 positive	Esophageal Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
HER-2 positive	Endometrial Cancer	HER-2 positive	Endometrial Cancer	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab Sensitive: A2 - Guideline pertuzumab Sensitive : A2	pertuzumab Sensitive: A2 - Guideline pertuzumab Sensitive : A2

HER-2 positive

Associations